Cited by 371Blood Coagulation and Thrombosis MechanismsAdipokines, Inflammation, and Metabolic DiseasesProtease and Inhibitor Mechanisms

The DOI matches its Crossref record; 95 of the 95 references it cites were found in a registry or an index.

Plasminogen activator inhibitor-1, inflammation, obesity, insulin resistance and vascular risk

Open access

Juhan-Vague, I., Alessi, M-C., Mavri, A., Morange, P.E.·2003·Journal of Thrombosis and Haemostasis

DOI 10.1046/j.1538-7836.2003.00279.x

Open this paper in CoChat — free account

Abstract

Elevated plasma plasminogen activator inhibitor-1 (PAI-1) level is a core feature of insulin-resistance syndrome (IRS). Atherothrombotic complications in IRS are partly attributed to impaired fibrinolysis caused by increased plasma PAI-1 levels. Although the etiology of IRS is far from being explained, the clustering of inflammation, adipose tissue accumulation and insulin resistance suggests an etiopathological link. Proinflammatory cytokines might regulate PAI-1 expression in IRS; however, more studies are needed to confirm this complex mechanism in humans. Furthermore, modifying PAI-1 expression by PAI-1 inhibitors provides a new challenge and may reveal the true role of PAI-1 in atherosclerotic and insulin resistance processes.

Integrity signals

Registry

Crossref · 10.1046/j.1538-7836.2003.00279.x

Cites

95 of 95 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Effects of an Angiotensin-Converting–Enzyme Inhibitor, Ramipril, on Cardiovascular Events in High-Risk Patients
(2000) · New England Journal of Medicine · doi:10.1056/nejm200001203420301 · Cited by 8,663
Inflammation in atherosclerosis
Libby, P. (2002) · Nature · doi:10.1038/nature01323 · Cited by 8,315
Adipose Expression of Tumor Necrosis Factor-α: Direct Role in Obesity-Linked Insulin Resistance
Hotamisligil, G. S., Shargill, N. S., & Spiegelman, B. M. (1993) · Science · doi:10.1126/science.7678183 · Cited by 7,518
Prevalence of the Metabolic Syndrome Among US Adults: Findings From the Third National Health and Nutrition Examination Survey
Ford, E. S., Giles, W. H., & Dietz, W. H. (2002) · JAMA · doi:10.1001/jama.287.3.356 · Cited by 6,698
Cardiovascular Morbidity and Mortality Associated With the Metabolic Syndrome
Isomaa, B., Almgren, P., Tuomi, T., Forsén, B., Lahti, K., Nissén, M., Taskinen, M.-R., & Groop, L. (2001) · Diabetes Care · doi:10.2337/diacare.24.4.683 · Cited by 4,760
C-Reactive Protein, Interleukin 6, and Risk of Developing Type 2 Diabetes Mellitus
Pradhan, A. D. (2001) · JAMA · doi:10.1001/jama.286.3.327 · Cited by 4,433
PPAR-γ agonists inhibit production of monocyte inflammatory cytokines
Jiang, C., Ting, A. T., & Seed, B. (1998) · Nature · doi:10.1038/34184 · Cited by 2,899
IRS-1-Mediated Inhibition of Insulin Receptor Tyrosine Kinase Activity in TNF-α- and Obesity-Induced Insulin Resistance
Hotamisligil, G. S., Peraldi, P., Budavari, A., Ellis, R., White, M. F., & Spiegelman, B. M. (1996) · Science · doi:10.1126/science.271.5249.665 · Cited by 2,630
C-Reactive Protein in Healthy Subjects: Associations With Obesity, Insulin Resistance, and Endothelial Dysfunction: A Potential Role for Cytokines Originating From Adipose Tissue?
Yudkin, J. S., Stehouwer, C. D. A., Emeis, J. J., & Coppack, S. W. (1999) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.19.4.972 · Cited by 2,465
Chronic Subclinical Inflammation as Part of the Insulin Resistance Syndrome
Festa, A., D’Agostino, R., Howard, G., Mykkänen, L., Tracy, R. P., & Haffner, S. M. (2000) · Circulation · doi:10.1161/01.cir.102.1.42 · Cited by 2,366

Show all 95 references

Research works printed but not linked: 1

Mohamed-Ali, 1997, Human subcutaneous adipose tissue secretes interleukin-6 but not tumour necrosis factor-αin vivo, J Clin Endocrinol Metab, 82, 4196

Sorted by citations

Items 101–200 of 369

Impact of Metabolic Syndrome on the Short-Term Outcomes of Colorectal Cancer Surgery
Lohsiriwat, V., Pongsanguansuk, W., Lertakyamanee, N., & Lohsiriwat, D. (2010) · Diseases of the Colon & Rectum · doi:10.1007/dcr.0b013e3181bdbc32 · Cited by 44
“AHA/NHBLI criteria for clinical diagnosis of MS Clinical measure Categorical cutpoints Elevated WC 40 inches in males 35 inches in females Elevated BP 130 mmHg systolic BP or 85 mmHg diastolic BP or Receiving antihypertensive drug treatment in a patient with a history of hypertension Elevated TG 150 mg/dL or Receiving…”
BackgroundInfluential
Tissue Plasminogen Activator, von Willebrand Factor, and Risk of Type 2 Diabetes in Older Men
Wannamethee, S. G., Sattar, N. A., Rumley, A., Whincup, P. H., LENNON, L. T., & Lowe, G. D. O. (2008) · Diabetes Care · doi:10.2337/dc07-1569 · Cited by 45
Salvianolic acid B attenuates plasminogen activator inhibitor type 1 production in TNF‐α treated human umbilical vein endothelial cells
Zhou, Z., Liu, Y., Miao, A., & Wang, S. (2005) · Journal of Cellular Biochemistry · doi:10.1002/jcb.20567 · Cited by 45
“Previous studies emphasizing the pathophysiological roles of PAI-1 seem to suggest that modulation of endothelial PAI-1 expressionmay represent an attractive therapeutic approach for atherosclerosis [Juhan-Vague et al., 2003].”
Background
Autocrine and paracrine up-regulation of blood–brain barrier function by plasminogen activator inhibitor-1
Dohgu, S., Takata, F., Matsumoto, J., Oda, M., Harada, E., Watanabe, T., Nishioku, T., Shuto, H., Yamauchi, A., & Kataoka, Y. (2010) · Microvascular Research · doi:10.1016/j.mvr.2010.10.004 · Cited by 44
“Regulation of PAI-1 production is inducible rather than constitutive (Juhan-Vague et al., 2003).”
Background
Hepatotoxicity of tocilizumab and anakinra in rheumatoid arthritis: management decisions
Mahmud, M., Safadi, R., & Mader, R. (2011) · Clinical Pharmacology Advances and Applications · doi:10.2147/cpaa.s24004 · Cited by 43
Gpr75 ‐deficient mice are protected from high‐fat diet–induced obesity
Hossain, S., Gilani, A., Pascale, J. V., Villegas, E., Diegisser, D., Agostinucci, K. J., Kulaprathazhe, M., Dirice, E., Garcia, V. G., & Schwartzman, M. L. (2023) · Obesity · doi:10.1002/oby.23692 · Cited by 41
“Likewise, levels of plasminogen activator inhibitor 1 (PAI-1), which has been characterized as a functional biomarker of metabolic syndrome [24, 25], displayed a twofold increase in response to HFD in WT but not in HET or KO mice (Figure 5E).”
Background
Plasminogen activator inhibitor‐1 is independently associated with non‐alcoholic fatty liver disease whereas leptin and adiponectin vary between genders
Chang, M., Hsu, C., Tseng, J., Tsou, Y., Chen, S., Shiau, S., Yeh, C., & Chiu, C. (2014) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.12705 · Cited by 42
Evaluation of PAI-039 [{1-Benzyl-5-[4-(trifluoromethoxy)phenyl]-1 H-indol-3-yl}(oxo)acetic Acid], a Novel Plasminogen Activator Inhibitor-1 Inhibitor, in a Canine Model of Coronary Artery Thrombosis
Hennan, J. K., Elokdah, H. M., Leal, M., Ji, A., Friedrichs, G. S., Morgan, G. A., Swillo, R. E., Antrilli, T. M., Hreha, A. L., & Crandall, D. L. (2005) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.105.084129 · Cited by 42
Laboratory Parameters of Hemostasis, Adhesion Molecules, and Inflammation in Type 2 Diabetes Mellitus: Correlation with Glycemic Control
Palella, E., Cimino, R., Pullano, S. A., Fiorillo, A. S., Gulletta, E., Brunetti, A., Foti, D. P., & Greco, M. (2020) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph17010300 · Cited by 48
“Also, a link between PAI-1 and atherothrombosis via obesity and insulin resistance has been definitely assessed, being visceral fat a major regulator of PAI-1 [29,30].”
Background
Adipokines and cardiometabolic function: How are they interlinked?
Schutte, A. E., Huisman, H. W., Schutte, R., van Rooyen, J. M., Malan, L., Fourie, C. M. T., & Malan, N. T. (2010) · Regulatory Peptides · doi:10.1016/j.regpep.2010.06.008 · Cited by 41
The plasminogen activator inhibitor (PAI-1) 4G/5G promoter polymorphism and PAI-1 levels in ischemic stroke
Gómez-García, E. B., Leebeek, F. W. G., Brouwers, G., Koudstaal, P. J., Dippel, D. W. J., & van Goor, M. P. J. (2004) · Thrombosis and Haemostasis · doi:10.1160/th04-09-0560 · Cited by 40
“This syndrome is defined as a cluster of abnormalities, which includes obesity, glucose intolerance and dyslipidemia and which is strongly related with low grade inflammation (24).”
Background
Blood glucose lowering by means of lifestyle intervention has different effects on adipokines as compared with insulin treatment in subjects with type 2 diabetes
Aas, A., Seljeflot, I., Torjesen, P. A., Diep, L. M., Thorsby, P. M., & Birkeland, K. I. (2006) · Diabetologia · doi:10.1007/s00125-006-0205-8 · Cited by 40
“Population studies have shown strong associations between indices of inflammation, abnormal lipid and carbohydrate metabolism, obesity and insulin resistance [4–8].”
Background
New markers in metabolic syndrome
Son, D., Ha, H., Park, H., Kim, H.-Y., & Lee, Y. (2022) · Advances in clinical chemistry · doi:10.1016/bs.acc.2022.06.002 · Cited by 39
Epidemiology and Incidence: The Scope of the Problem and Risk Factors for Development of Venous Thromboembolism
Stein, P. D., & Matta, F. (2011) · Critical Care Clinics · doi:10.1016/j.ccc.2011.09.006 · Cited by 39
Fibronectin, Plasminogen Activator Inhibitor Type 1 (PAI-1) And Uterine Artery Doppler Velocimetry as Markers of Preeclampsia
Bodova, K. B., Biringer, K., Dókuš, K., Ivanková, J., Staško, J., & Danko, J. (2011) · Disease Markers · doi:10.1155/2011/219350 · Cited by 39
Central Obesity, the Metabolic Syndrome, and Plasminogen Activator Inhibitor‐1 in Young Adults
Appel, S. J., Harrell, J. S., & Davenport, M. L. (2005) · Journal of the American Academy of Nurse Practitioners · doi:10.1111/j.1745-7599.2005.00083.x · Cited by 39
Diabetic and Metabolic Programming: Mechanisms Altering the Intrauterine Milieu
Eberle, C., & Ament, C. (2012) · ISRN Pediatrics · doi:10.5402/2012/975685 · Cited by 38
“Next to cumulative cytokine productions, there are further stimuli, such as oxidative stress and endothelial injury, which are disbalancing metabolic conditions towards dysmetabolic environment [34, 43, 60, 61].”
Background
Anti-inflammatory agents as modulators of the inflammation in adipose tissue: A systematic review
Nascimento, S. S. D. C., de Queiroz, J. L. C., de Medeiros, A. F., Nunes, A. C. D. F., Piuvezam, G., Maciel, B. L. L., Passos, T. S., & Morais, A. H. D. A. (2022) · PLoS ONE · doi:10.1371/journal.pone.0273942 · Cited by 37
Relationship of waist and hip circumference with coagulation and fibrinolysis in postmenopausal women
Peverill, R. E., Teede, H. J., Malan, E., Kotsopoulos, D., Smolich, J. J., & McGrath, B. P. (2007) · Clinical Science · doi:10.1042/cs20070084 · Cited by 36
n3 PUFAs Do Not Affect Adipose Tissue Inflammation in Overweight to Moderately Obese Men and Women1–3
Kratz, M., Kuzma, J. N., Hagman, D. K., van Yserloo, B., Matthys, C. C., Callahan, H. S., & Weigle, D. S. (2013) · The Journal of Nutrition · doi:10.3945/jn.113.174383 · Cited by 35
“We also included inducible nitric oxide synthase (NOS2), an enzyme produced by classically activated macrophages (16) and plasminogen activator inhibitor 1 (PAI-1), a risk factor for cardiovascular disease that is elevated in humans in instances of acute inflammation (17) and the expression of which is increased by pr…”
Background
The association of serum C-reactive protein, uric acid and magnesium with insulin resistance in Chinese postmenopausal women with prediabetes or early untreated diabetes
Liu, Z., & Ho, S. C. (2011) · Maturitas · doi:10.1016/j.maturitas.2011.07.007 · Cited by 35
Transcriptome analysis of subcutaneous adipose tissues in beef cattle using 3′ digital gene expression-tag profiling1
Jin, W., Olson, E. N., Moore, S. S., Basarab, J. A., Basu, U., & Guan, L. L. (2011) · Journal of Animal Science · doi:10.2527/jas.2011-4229 · Cited by 35
Visceral adipose tissue-directed FGF21 gene therapy improves metabolic and immune health in BTBR mice
Queen, N. J., Bates, R., Huang, W., Xiao, R., Appana, B., & Cao, L. (2020) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2020.12.011 · Cited by 38
“Plasminogen activator inhibitor-1 (PAI-1) is involved in fibrinolysis and its elevation thought to contribute to vascular disease and inflammation in obese states.(44,45) PAI-1 levels were reduced in the Rec2FGF21 group (Figure 5L), indicative of improved metabolic function and reduced inflammation.”
Background
Hemostatic abnormalities associated with obesity and the metabolic syndrome
Reaven, G. M. (2005) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2005.01277.x · Cited by 35
Elevated plasminogen activator inhibitor 1 in sleep apnea and its relation to the metabolic syndrome: an investigation in 2 different study samples
von Känel, R., Loredo, J. S., Ancoli‐Israel, S., Mills, P. J., & Dimsdale, J. E. (2007) · Metabolism · doi:10.1016/j.metabol.2007.02.010 · Cited by 34
“These findings corroborate previous studies [1214,27-29] and are in agreement with the notion that elevated PAI-1 could contribute to increased atherothrombotic risk in OSA [9] and the metabolic syndrome [20].”
Result
The relationship among TAFI, t-PA, PAI-1 and F1 + 2 in type 2 diabetic patients with normoalbuminuria and microalbuminuria
Chudý, P., Kotuličová, D., Staško, J., & Kubisz, P. (2011) · Blood Coagulation & Fibrinolysis · doi:10.1097/mbc.0b013e328346f8ca · Cited by 34
A Profibrotic Effect of Plasminogen Activator Inhibitor Type-1 (PAI-1) in the Heart
Zaman, A. K. M. T., French, C. J., Schneider, D. J., & Sobel, B. E. (2009) · Experimental Biology and Medicine · doi:10.3181/0811-rm-321 · Cited by 33
“Conditions such as type 2 diabetes and insulin resistance accompanying obesity are associated with altered expression of plasminogen activator inhibitor type-1 (PAI1) in patients (1, 2) and in the hearts of mice subjected to myocardial infarction (MI) (3).”
Background
Plasminogen activator inhibitor-1 is elevated in patients with COPD independent of metabolic and cardiovascular function
Waschki, B., Watz, H., Holz, O., MAGNUSSEN, H., Olejnicka, B. T., Welte, T., Rabe, K. F., & Janciauskiene, S. M. (2017) · International Journal of COPD · doi:10.2147/copd.s128689 · Cited by 33
“In addition, higher level of PAI-1 is associated with obesity, insulin resistance, diabetes, hyperlipidemia, and premature aging.(5,9,10) All these conditions are prevalent in COPD,(11,12) and a potential influence of PAI-1 on an enhanced thrombogenesis in COPD has been hypothesized.”
Plasminogen Activator Inhibitor-1 Level Correlates with Lipoprotein Subfractions in Obese Nondiabetic Subjects
Somodi, S., Seres, I., Lőrincz, H., Harangi, M., Fülöp, P., & Paragh, G. (2018) · International Journal of Endocrinology · doi:10.1155/2018/9596054 · Cited by 33
Adipokines (adiponectin and plasminogen activator inhhibitor-1) in metabolic syndrome
Mk, G., Dutta, M., & Mahalle, N. P. (2011) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/2230-8210.91206 · Cited by 32
“[27,39,43,46] In univariate regression analysis, PAI-1 was positively associated with BMI, BFM and PBF, and negatively associated with BMR.”
Method
Nutrition and hemostasis: A focus on urbanization in South Africa
Pieters, M., & Vorster, H. H. (2007) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.200700373 · Cited by 32
CCAAT/enhancer binding protein α, β and δ gene variants: associations with obesity related phenotypes in the Leeds Family Study
Bennett, C. E., Nsengimana, J., Bostock, J. A., Cymbalista, C. M., Futers, T. S., Knight, B. L., McCormack, L. J., Prasad, U. K., Riches‐Suman, K., Rolton, D. J., et al. (2010) · Diabetes and Vascular Disease Research · doi:10.1177/1479164110366274 · Cited by 32
“In addition, we also demonstrated weak association between CEBPA 1558A and decreased PAI-1, an inhibitor of fibrinolysis which has been shown to be produced by adipocytes(56) and is associated with obesity and related metabolic abnormalities.(57) Recently Olofsson et al.”
Background
Insulin and glucose play a role in foam cell formation and function.
Shashkin, P. N., Jain, N., Miller, Y. I., Rissing, B. A., Huo, Y., Keller, S. R., Vandenhoff, G. E., Nadler, J. L., & McIntyre, T. M. (2006) · Cardiovascular Diabetology · doi:10.1186/1475-2840-5-13 · Cited by 32
“Hypersecretion of IL-6 and TNFα may exert major stimulatory effects on the synthesis of acute-phase proteins such as PAI-1, which is also related to insulin resistance [56].”
Research advances in the therapy of metabolic syndrome
Lin, Z., & Sun, L. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1364881 · Cited by 33
Hepatotoxicity due to tocilizumab and anakinra in rheumatoid arthritis: two case reports
Mahmud, M., Safadi, R., & Paz, C. (2011) · International Journal of General Medicine · doi:10.2147/ijgm.s23920 · Cited by 30
“9,8 Therefore, interleukin-6 signaling is currently the best characterized pathway thought to be associated with hepatoprotection.”
Influential
Low carbohydrate diet: are concerns with saturated fat, lipids, and cardiovascular disease risk justified?
Diamond, D. M., O’Neill, B. J., & Volek, J. S. (2020) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000568 · Cited by 34
Improved endothelial function with simvastatin but unchanged insulin sensitivity with simvastatin or ezetimibe
Kater, A. L. D. A., Batista, M. C., & Ferreira, S. R. G. (2010) · Metabolism · doi:10.1016/j.metabol.2010.02.011 · Cited by 31
Cognitive‐behavioural stress management does not improve biological cardiovascular risk indicators in women with ischaemic heart disease: a randomized‐controlled trial
Claesson, M., Birgander, L. S., Jansson, J.-H., Lindahl, B., Burell, G. K., Asplund, K., & MATTSSON, C. (2006) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2006.01691.x · Cited by 31
A Proteomics Based Approach Reveals Differential Regulation of Visceral Adipose Tissue Proteins between Metabolically Healthy and Unhealthy Obese Patients
Alfadda, A. A., Masood, A., Al-Naami, M. Y., Chaurand, P., & Benabdelkamel, H. (2017) · Molecules and Cells · doi:10.14348/molcells.2017.0073 · Cited by 30
“Juhan-Vague et al have shown that an increase in PAI-1 levels are strongly associated with BMI, visceral fat, blood pressure, plasma levels of insulin or pro-insulin, triglycerides, small dense LDL particles, free fatty acids, and HDL cholesterol (Juhan-Vague et al., 2003).”
Background
Characterization of TGF-β expression and signaling profile in the adipose tissue of rats fed with high-fat and energy-restricted diets
Sousa‐Pinto, B., Gonçalves, L., Rodrigues, A. R., Tomada, I., Almeida, H., Neves, D., & Gouveia, A. (2016) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2016.07.017 · Cited by 30
“One of those mediators, whose transcription is also promoted in vivo by TGF-β, is the plasminogen activator inhibitor (PAI-1), which is associatedwith insulin resistance, obesity and thrombogenic risk [17–19].”
Background
Inhibitory effects of harpagoside on TNF-α-induced pro-inflammatory adipokine expression through PPAR-γ activation in 3T3-L1 adipocytes
Kim, T. K., & Park, K. S. (2015) · Cytokine · doi:10.1016/j.cyto.2015.05.015 · Cited by 29
“Plasma levels of PAI-1 are markedly elevated in obese individuals as well as in patients with insulin resistance, type 2 diabetes, and cardiovascular diseases hrough (CVDs) [15,16].”
Background
Metabolic syndrome: A review of emerging markers and management
Singh, B. K., Arora, S., Goswami, B., & Mallika, V. (2009) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2009.04.012 · Cited by 29
Association of arterial events with the coexistence of metabolic syndrome and primary antiphospholipid syndrome
Rodrigues, C. E. M., Bonfá, E., Caleiro, M. T. C., Vendramini, M. B. G., Bueno, C., Lopes, J. B., & de Carvalho, J. F. (2012) · Arthritis Care & Research · doi:10.1002/acr.21701 · Cited by 29
Heart failure and inflammation-related biomarkers as predictors of new-onset diabetes in the general population
Suthahar, N., Meijers, W. C., Brouwers, F. P. J., Heerspink, H. J. L., Gansevoort, R. T., van der Harst, P., Bakker, S. J. L., & de Boer, R. A. (2017) · International Journal of Cardiology · doi:10.1016/j.ijcard.2017.10.035 · Cited by 29
Improvement of cardiovascular risk factors in patients with type 2 diabetes after long‐term continuous subcutaneous insulin infusion
Noh, Y., Lee, S., Kim, E., Kim, D., Lee, H. I., Lee, J., Lee, J. H., Park, S., Koo, J., Wang, J., et al. (2008) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.849 · Cited by 28
Metabolic Syndrome and Prediabetes
Babu, A. R., & Fogelfeld, L. A. (2006) · Disease-a-Month · doi:10.1016/j.disamonth.2006.03.001 · Cited by 27
Expression of TNF-α protein in omental and subcutaneous adipose tissue in obesity
Cao, Y. L., Hu, C., Meng, X., Wang, D. F., & Zhang, J. (2007) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2007.08.030 · Cited by 28
Plasminogen Activator Inhibitor-1 (PAI-1) Gene Polymorphism (-675 4G/SG) Associated with Obesity and Vascular Risk in Children
Berberoğlu, M., Evliyaoğlu, O., Adıyaman, P., Öçal, G., Ulukol, B., Şimşek, F., Şıklar, Z., Ergür, A. T., Özel, D., & Akar, N. (2006) · Journal of Pediatric Endocrinology and Metabolism · doi:10.1515/jpem.2006.19.5.741 · Cited by 28
Pancreas-Kidney transplantation: Impact of dialysis modality on the outcome
Martins, L. S., Malheiro, J., Pedroso, S., Almeida, M., Dias, L., Henriques, A. C., Silva, D. S., Davide, J., Cabrita, A., Noronha, I. L., et al. (2015) · Transplant International · doi:10.1111/tri.12565 · Cited by 27
“Additionally, impaired fibrinolysis caused by increased plasma plasminogen activator inhibitor-1 (PAI-1) levels is linked with insulin resistance that occurs with uremia and might be exacerbated in certain PD patients [27].”
Background
Agrimonia pilosa Ledeb. aqueous extract improves impaired glucose tolerance in high-fat diet-fed rats by decreasing the inflammatory response
Jang, H., Nam, S. Y., Kim, M. J., Kim, J. B., Choi, J. S., Kim, H. R., & Lee, Y. M. (2017) · BMC Complementary and Alternative Medicine · doi:10.1186/s12906-017-1949-z · Cited by 27
“Serpine1 encodes PAI-1, and elevated serum PAI-1 levels are strongly correlated with insulin resistance and liver steatosis [25].”
Background
Platelet perturbations in diabetes: implications for cardiovascular disease risk and treatment
Mathewkutty, S., & McGuire, D. K. (2009) · Expert Review of Cardiovascular Therapy · doi:10.1586/erc.09.30 · Cited by 26
Approach to the diagnosis and management of lipoprotein disorders
Al-Waili, K., Al‐Rasadi, K., Awan, Z. A., & Genest, J. J. (2009) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0b013e328329135a · Cited by 26
Relationships of PAI-1 levels to central obesity and liver steatosis in a sample of adult male population in southern Italy
Barbato, A., Iacone, R., Tarantino, G., Russo, O., Sorrentino, P., Avallone, S., Galletti, F., Farinaro, E., Valle, E. D., & Strazzullo, P. (2009) · Internal and Emergency Medicine · doi:10.1007/s11739-009-0240-9 · Cited by 26
“They are associated with visceral obesity, in both experimental animal models and humans [1, 12, 13], with insulin resistance [14] and with metabolic syndrome (MS) defined according to NCEP-ATPIII criteria [15].”
Background
Earlier onset of diabesity‐Induced adverse cardiac remodeling in female compared to male mice
Bowden, M. A., Tesch, G. H., Julius, T. L., Rosli, S., Love, J. E., & Ritchie, R. H. (2015) · Obesity · doi:10.1002/oby.21072 · Cited by 26
“PAI-I expression is reportedly increased in settings of T2DM (38); our data in diabetic myocardium is consistent with these prior observations.”
Result
PAI-1 and TNF-α profiles of adipose tissue in obese cardiovascular disease patients.
Gazioğlu, S. B., Akan, G., Atalar, F., & Erten, G. (2015) · PubMed Central · Cited by 26
3-Iodothyronamine and Derivatives: New Allies Against Metabolic Syndrome?
Rutigliano, G., Bandini, L., Sestito, S., & Chiellini, G. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21062005 · Cited by 26
Peripheral insulin resistance in patients with Behçet's disease
Erdem, H., Dinç, A., Pay, S., Şimşek, İ., & Turan, M. (2006) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/j.1468-3083.2006.01457.x · Cited by 26
Deleterious effects of lack of cardiac PAI-1 after coronary occlusion in mice and their pathophysiologic determinants
Zaman, A. K. M. T., Fujii, S., Schneider, D. J., Taatjes, D. J., LIJNEN, H. R., & Sobel, B. E. (2007) · Histochemistry and Cell Biology · doi:10.1007/s00418-007-0300-z · Cited by 26
“Thus, PAI-1 expression increases with insulin resistance and type 2 diabetes in patients (Juhan-Vague et al. 2003; McGill et al. 1994; Sobel et al. 1998) and in laboratory animals (Nordt et al. 1995).”
Background
Imbalance between protective (adiponectin) and prothrombotic (Plasminogen Activator Inhibitor-1) adipokines in metabolic syndrome
Ahirwar, A. K., Jain, A., Goswami, B., Bhatnagar, M. K., & Bhatacharjee, J. (2014) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2014.04.035 · Cited by 25
Behçet’s disease: new insight into the relationship between procoagulant state, endothelial activation/damage and disease activity
Bello, I. F., López-Longo, F. J., Arias‐Salgado, E. G., Jiménez‐Yuste, V., & Butta, N. V. (2013) · Orphanet Journal of Rare Diseases · doi:10.1186/1750-1172-8-81 · Cited by 25
“Systemic inflammation as presented in BD could increase PAI-1 levels [39,40].”
Background
Thrombosis Complications in Pediatric Acute Lymphoblastic Leukemia: Risk Factors, Management, and Prevention: Is There Any Role for Pharmacologic Prophylaxis?
Rodriguez, V. (2022) · Frontiers in Pediatrics · doi:10.3389/fped.2022.828702 · Cited by 24
“Several hemostatic alterations have been observed in obese individuals that can explain the thrombosis elevated risk such as altered fibrinolysis, increased plasminogen activator inhibitor (PAI-1), increased platelet aggregability, through elevations of von Willebrand factor, protein C resistance and higher levels of…”
BackgroundInfluential
Prostate cancer survivors with symptoms of radiation cystitis have elevated fibrotic and vascular proteins in urine
Zwaans, B. M. M., Nicolai, H. E., Chancellor, M. B., & Lamb, L. E. (2020) · PLoS ONE · doi:10.1371/journal.pone.0241388 · Cited by 24
Use of thrombin-based hemostatic matrix during meningioma resection: A potential risk factor for perioperative thromboembolic events
Safaee, M., Sun, M. Z., Oh, T., Aghi, M. K., Berger, M. S., McDermott, M. W., Parsa, A. T., & Bloch, O. G. (2014) · Clinical Neurology and Neurosurgery · doi:10.1016/j.clineuro.2014.01.021 · Cited by 24
Circulatory Syndrome: An Evolution of the Metabolic Syndrome Concept!
Khoshdel, A., Carney, S. L., & Gillies, A. H. B. (2012) · Current Cardiology Reviews · doi:10.2174/157340312801215773 · Cited by 24
“Additionally insulin and lipids may have direct effects on inhibition of coagulation and platelet function through the nitric oxide pathway, which is impaired in patients with diabetes [141].”
Background
Impact of Helicobacter pylori and metabolic syndrome on mast cell activation-related pathophysiology and neurodegeneration
Kountouras, J., Boziki, M. K., Kazakos, E. I., Theotokis, P., Kesidou, E., Nella, M., Bakirtzis, C., Karafoulidou, E., Vardaka, E., Mouratidou, M. C., et al. (2024) · Neurochemistry International · doi:10.1016/j.neuint.2024.105724 · Cited by 23
Impact of a moderate-intensity walking program on cardiometabolic risk markers in overweight to obese women
Riesco, É., Tessier, S., Lacaille, M., Pérusse, F., Côté, M., Després, J., Bergeron, J., Weisnagel, J. S., Doré, J., & Mauriège, P. (2012) · Menopause The Journal of The North American Menopause Society · doi:10.1097/gme.0b013e31826f7ebf · Cited by 22
“Moreover, abnormalities in fibrinolysis (such as high plasma plasminogen activator inhibitor-1 [PAI-1], also produced by AT) and fibrinogen levels may also be involved in the increased CHD risk.(8) Although it is not fully understood how menopause interferes with the expression of”
Background
PAI-1 Levels are Related to Insulin Resistance and Carotid Atherosclerosis in Subjects with Familial Combined Hyperlipidemia
Carratalá, A., Martínez‐Hervás, S., Borja, E. R., Benito, E., Real, J. T., Sáez, G. T., Carmena, R., & Ascaso, J. F. (2017) · Journal of Investigative Medicine · doi:10.1136/jim-2017-000468 · Cited by 22
Exposure to Low Doses of Dechlorane Plus Promotes Adipose Tissue Dysfunction and Glucose Intolerance in Male Mice
Peshdary, V., Styles, G., Rigden, M. D., Caldwell, D., Kawata, A., Sorisky, A., & Atlas, E. (2020) · Endocrinology · doi:10.1210/endocr/bqaa096 · Cited by 22
Role of fibrinolytic and clotting parameters in the diagnosis of liver veno-occlusive disease after hematopoietic stem cell transplantation in a pediatric population
Spiezia, L., Cesaro, S., Messina, C., Paris, M. K., Pillon, M., Saggiorato, G., Pagnan, A., Girolami, A., Zanesco, L., Cella, G., et al. (2005) · Thrombosis and Haemostasis · doi:10.1160/th04-09-0621 · Cited by 22
Antithrombotic Effects of Rosiglitazone‐Metformin versus Glimepiride‐Metformin Combination Therapy in Patients with Type 2 Diabetes Mellitus and Metabolic Syndrome
Derosa, G., Gaddi, A. V., Piccinni, M. N., Ciccarelli, L., SALVADEO, S. A. T., Peros, E., Ghelfi, M., Ferrari, I., & Cicero, A. F. G. (2005) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.25.5.637.63587 · Cited by 22
Aging and Adiposity—Focus on Biological Females at Midlife and Beyond
Rehman, A., Lathief, S., Charoenngam, N., & Pal, L. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25052972 · Cited by 24
“PAI-1 is expressed by adipocytes, and its secretion is greater in the VAT relative to the SAT [53].”
Background
Adipocytokines as features of the metabolic syndrome determined using confirmatory factor analysis
Smits, M. M., Woudstra, P., Utzschneider, K. M., Tong, J., Gerchman, F., Faulenbach, M. V., Carr, D. B., Aston‐Mourney, K., Chait, A., Knopp, R. H., et al. (2013) · Annals of Epidemiology · doi:10.1016/j.annepidem.2013.03.001 · Cited by 21
“PAI-1 is an important mediator in the hemostatic pathway [19] and has been shown to be an acute-phase protein [35].”
Background
Meta-Review of Protein Network Regulating Obesity Between Validated Obesity Candidate Genes in the White Adipose Tissue of High-Fat Diet-Induced Obese C57BL/6J Mice
Kim, E., Kim, E. J., Seo, S.-W., Hur, C., McGregor, R. A., & Choi, M. (2013) · Critical Reviews in Food Science and Nutrition · doi:10.1080/10408398.2011.619283 · Cited by 22
Metabolic Syndrome in the Pediatric Population: A Short Overview
Varda, N. M., & Gregorič, A. (2009) · Pediatric Reports · doi:10.4081/pr.2009.e1 · Cited by 21
“with atherogenesis are fibrinogen and plasminogen activator inhibitor-1.(64) The latter is also associated with type 2 diabetes.”
Background
Differences in the association of PAI-1 activity with the metabolic syndrome between African and Caucasian women
Greyling, A., Pieters, M., Hoekstra, T., Oosthuizen, W., & Schutte, A. E. (2006) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2006.04.006 · Cited by 21
Ketosis Suppression and Ageing (KetoSAge): The Effects of Suppressing Ketosis in Long Term Keto-Adapted Non-Athletic Females
Cooper, I. D., Kyriakidou, Y., Edwards, K., Petagine, L., Seyfried, T. N., Duraj, T., Soto-Mota, A., Scarborough, A., Jacome, S. L., Brookler, K. H., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms242115621 · Cited by 20
“Disseminated intravascular coagulopathy (DIC) and thrombosis cause blockages of the blood ﬂow to either the heart or brain, resulting in insufﬁcient blood supply as well as increased atherosclerosis [93].”
Background
The endocrine role of adipose tissue: focus on adiponectin and resistin
Jackson, M. B., Osei, S. Y., & Ahima, R. S. (2005) · Current Opinion in Endocrinology & Diabetes · doi:10.1097/01.med.0000159113.87201.e8 · Cited by 21
Body fatness and endogenous sex hormones in the menopausal transition
Zsákai, A., Karkus, Z., Utczás, K., Biri‐Kovács, B., Sievert, L. L., & Bodzsar, E. B. (2016) · Maturitas · doi:10.1016/j.maturitas.2016.02.006 · Cited by 20
Western diet given to healthy rats mimics the human phenotype of diabetic cardiomyopathy
Verboven, M., Deluyker, D., Ferferieva, V., Lambrichts, I., Hansen, D., Eijnde, B. O., & Bito, V. (2018) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2018.08.002 · Cited by 21
The estimation of selected endogenous anticoagulation system parameters in patients with subclinical Cushing's syndrome
Świątkowska−Stodulska, R., Kaniuka‐Jakubowska, S., Wiśniewski, P., Skibowska‐Bielińska, A., & Sworczak, K. (2011) · European Journal of Endocrinology · doi:10.1530/eje-11-0535 · Cited by 20
Dietary Mg Supplementation Decreases Oxidative Stress, Inflammation, and Vascular Dysfunction in an Experimental Model of Metabolic Syndrome with Renal Failure
López‐Baltanás, R., Rodríguez-Ortiz, M. E., Díaz‐Tocados, J. M., Martinez-Moreno, J. M., Membrives, C., Rodelo‐Haad, C., de Mier, M. V. P.-R., Rodríguez, M., Canalejo, A., Almadén, Y., et al. (2023) · Antioxidants · doi:10.3390/antiox12020283 · Cited by 19
“Obesity and impaired glucose and lipid metabolism favor the release of cytokines from adipose tissue, leading to an inflammatory state [5,6] with an increase of reactive oxygen species (ROS) [7].”
Background
Dysregulation of Insulin-Linked Metabolic Pathways in Alzheimer’s Disease: Co-Factor Role of Apolipoprotein E ɛ 4
Robbins, J., Busquets, O., Tong, M., & de la Monte, S. M. (2020) · Journal of Alzheimer s Disease Reports · doi:10.3233/adr-200238 · Cited by 19
The association of inflammatory and fibrinolytic proteins with 5 year change in insulin clearance: the Insulin Resistance Atherosclerosis Study (IRAS)
Lee, C. C., Lorenzo, C., Haffner, S. M., Wagenknecht, L. E., Festa, A., Goodarzi, M. O., Stefanovski, D., Olson, N. C., Norris, J. M., Rewers, M., et al. (2012) · Diabetologia · doi:10.1007/s00125-012-2741-8 · Cited by 18
“It is well established that higher plasma PAI-1 is a central feature of metabolic syndrome [26], and higher levels prevail through the continuum of insulin resistance, from impaired glucose tolerance to diabetes [27].”
Background
Effects of transdermal testosterone administration on insulin sensitivity, fat mass and distribution, and markers of inflammation and thrombolysis in human immunodeficiency virus–infected women with mild to moderate weight loss
Herbst, K. L., Calof, O. M., Hsia, S. H., Sinha‐Hikim, I., Woodhouse, L. J., Buchanan, T. A., & Bhasin, S. (2006) · Fertility and Sterility · doi:10.1016/j.fertnstert.2006.01.010 · Cited by 18
The impact of metabolic syndrome and CRP on vascular phenotype in type 2 diabetes mellitus
Dehnavi, R. A., Beishuizen, E. D., van de Ree, M. A., le Cessie, S., Huisman, M. V., Kluft, C., Princen, H. M. G., & Tamsma, J. T. (2007) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2007.06.011 · Cited by 17
“This has partly been attributed to impaired fibrinolytic function [27] due to altered regulation of PAI-1, tPA, and fibrinogen [28,33,34].”
Background
11β‐Hydroxysteroid dehydrogenase type 1‐driven cortisone reactivation regulates plasminogen activator inhibitor type 1 in adipose tissue of obese women
AYACHI, S. E., Paulmyer‐Lacroix, O., Verdier, M., Alessi, M., Dutour, A., & Grino, M. (2006) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2006.01811.x · Cited by 17
Self-citation
Pathogenesis of obesity-associated cardiovascular diseases: Key role of biomolecules
Sood, S., Mittal, N., Singh, T. G., & Devi, S. (2023) · Health Sciences Review · doi:10.1016/j.hsr.2023.100098 · Cited by 17
Resistin regulates the expression of plasminogen activator inhibitor-1 in 3T3-L1 adipocytes
Ikeda, Y., Tsuchiya, H., Hama, S., Kajimoto, K., & Kogure, K. (2014) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2014.03.076 · Cited by 16
Assessment of plasminogen activator inhibitor-1 in obese Egyptian children
Mira, M. F., Anwar, G. M., Din, A. M. S. E., & Megahed, S. (2020) · Egyptian Pediatric Association Gazette · doi:10.1186/s43054-019-0012-8 · Cited by 16
Plasminogen activator inhibitor-1 and thrombin activatable fibrinolysis inhibitor levels in non-alcoholic steatohepatitis
Yener, S., Akarsu, M., Demir, T., Akıncı, B., Sağol, Ö., Bayraktar, F., Özcan, M. A., Tankurt, E., & Yeşil, S. (2007) · Journal of Endocrinological Investigation · doi:10.1007/bf03349221 · Cited by 16
Plasminogen activator inhibitor type 1 (PAI-1) is a valuable biomarker for predicting the metabolic syndrome (MS) in institutionalized elderly residents in Taiwan
Chou, Y., Sheu, W. H., Tang, Y., Chen, Y., Liao, S., Chuang, Y., Lin, C., & Chen, D. (2009) · Archives of Gerontology and Geriatrics · doi:10.1016/s0167-4943(09)70012-3 · Cited by 16
Synthesis and SAR of 2-carboxylic acid indoles as inhibitors of plasminogen activator inhibitor-1
Hu, B., Jetter, J. W., Wrobel, J. E., Antrilli, T. M., Bauer, J. S., Di, L., Polakowski, S., Jain, U., & Crandall, D. L. (2005) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2005.05.095 · Cited by 16
p38 MAPK inhibitors suppress biomarkers of hypertension end-organ damage, osteopontin and plasminogen activator inhibitor-1
Nerurkar, S. S., Olzinski, A. R., Frazier, K. S., Mirabile, R. C., O’Brien, S., Jing, J., Rajagopalan, D., Yue, T., & Willette, R. N. (2007) · Biomarkers · doi:10.1080/13547500600944930 · Cited by 16
Altered Daytime Fluctuation Pattern of Plasminogen Activator Inhibitor 1 in Type 2 Diabetes Patients with Coronary Artery Disease: A Strong Association with Persistently Elevated Plasma Insulin, Increased Insulin Resistance, and Abdominal Obesity
Lalic, K. S., Jotić, A., Rajkovic, N., Singh, S., Stošić, L., Popović, L., Lukić, L., Milicic, T. J., Seferović, J. P., Macesic, M. V., et al. (2015) · International Journal of Endocrinology · doi:10.1155/2015/390185 · Cited by 15
“In addition, increased concentration of PAI-1 in blood and arterial wall was also found in patients with obesity [6, 7], metabolic syndrome [8], and type 2 diabetes [9, 10].”
Background
An MRM-Based Multiplexed Quantification Assay for Human Adipokines and Apolipoproteins
Krieg, L., Schaffert, A., Kern, M., Landgraf, K., Wabitsch, M., Beck‐Sickinger, A. G., Körner, A., Blüher, M., von Bergen�, M., & Schubert, K. A. (2020) · Molecules · doi:10.3390/molecules25040775 · Cited by 15
Serum glucose and triglyceride determine high-risk subgroups in non-diabetic postinfarction patients
Corsetti, J. P., Zaręba, W., Moss, A. J., & Sparks, C. S. (2005) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2005.03.046 · Cited by 15
Role of BCL2-Associated Athanogene 1 in Differential Sensitivity of Human Endothelial Cells to Glucocorticoids
Mata‐Greenwood, E., Stewart, J. M., Steinhorn, R. H., & Pearce, W. J. (2013) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.113.301247 · Cited by 15
THE PATHOPHYSIOLOGY OF ENDOTHELIAL FUNCTION IN PREGNANCY AND THE USEFULNESS OF ENDOTHELIAL MARKERS
Slavík, L., Procházková, J., Procházka, M., Šimetka, O., Hluší, A., & Úlehlová, J. (2011) · Biomedical Papers · doi:10.5507/bp.2011.031 · Cited by 15
Folgeerkrankungen und Komplikationen der Adipositas
Dieterle, C. D., & Landgraf, R. (2005) · Der Internist · doi:10.1007/s00108-005-1552-0 · Cited by 14
Evaluation of pre-analytical, demographic, behavioural and metabolic variables on fibrinolysis and haemostasis activation markers utilised to assess hypercoagulability
Stegnar, M., Cuderman, T. V., & Mijovski, M. B. (2007) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm.2007.020 · Cited by 15
“The relationship between PAI-1 antigen, body constitution, plasma levels of tryglicerides and insulin is well established (38) and PAI-1 is therefore considered as a core feature of the insulin-resistance syndrome, also named metabolic syndrome (39).”

Authors: Juhan-Vague, I., Alessi, M.-C., Mavri, A., & Morange, P. E.
Affiliations: Inserm (FR)
Corresponding author: Juhan-Vague, I.
ORCID: Alessi, M-C.
Mavri, A.
Morange, P.E.
Venue: Journal of Thrombosis and Haemostasis
Publisher: Elsevier BV
Published: 2003-07
Volume: 1
Issue: 7
Pages: 1575-1579
ISSN: 1538-7836 (ISSN-L)
DOI: 10.1046/j.1538-7836.2003.00279.x
OpenAlex: W2042742088
Cited by: 371
References: 95
Citations by year: 2026: 9 · 2025: 13 · 2024: 13 · 2023: 8 · 2022: 14 · 2021: 6 · 2020: 11 · 2019: 14 · 2018: 10 · 2017: 17 · 2016: 9 · 2015: 19 · 2014: 14 · 2013: 11 · 2012: 13
FWCI: 4.40
Type: journal article
Language: en
Open access: bronze
doi.org
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
www.elsevier.com/legal/tdmrep-license (tdm)
www.elsevier.com/open-access/userlicense/1.0/ (vor, 7104 d)
Locations: Journal of Thrombosis and Haemostasis (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Hematology › Blood Coagulation and Thrombosis Mechanisms
Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adipokines, Inflammation, and Metabolic Diseases
Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Protease and Inhibitor Mechanisms
Keywords: plasminogen activator inhibitor-1, metabolic syndrome, inflammation, obesity, adipose tissue, inflammatory cytokines, impaired fibrinolysis, atherothrombosis, vascular risk, PAI-1 inhibitors, atherosclerosis
MeSH terms: Animals, Heart Diseases, Humans, Insulin Resistance, Obesity, Risk, Plasminogen Activator Inhibitor 1

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Plasminogen activator inhibitor-1, inflammation, obesity, insulin resistance and vascular risk

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks